T2-FLAIR mismatch sign correlates with
11C-methionine positron emission tomography
Glioma imaging
Lower-grade glioma
T2-FLAIR mismatch
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
04
07
2023
accepted:
07
08
2023
medline:
29
8
2023
pubmed:
17
8
2023
entrez:
17
8
2023
Statut:
ppublish
Résumé
The T2-FLAIR mismatch sign is recognized as an imaging finding highly suggestive of IDH-mutant astrocytomas. This study was designed to determine whether the T2-FLAIR mismatch sign correlates with uptake of We included 78 histopathologically verified lower-grade gliomas (grade 2: 31 cases, grade 3: 47 cases) in this study. 78 patients underwent The 78 lower-grade gliomas were assigned to one of three molecular groups: Group A (IDH-mutant and 1p/19q non-codeleted, n = 22), Group O (IDH-mutant and 1p/19q codeleted, n = 20), and Group W (IDH wildtype, n = 36). T2-FLAIR mismatch was found in 16 cases (20.5%) that were comprised of 8 (36.4%), 0 (0%), 8 (22.2%) cases in the molecular group A, O and W, respectively. The median T/N ratio of MET-PET in tumors with T2-FLAIR mismatch was 1.50, which was significantly lower than that of tumors without T2-FLAIR mismatch (1.83, p < 0.001, Mann-Whitney U test). In the Groups A and W (excluding Group O), the median T/N ratio on MET-PET in groups A and W (but not group O) with T2-FLAIR mismatch was 1.50, which was significantly lower than that of tumors without T2-FLAIR mismatch (1.81, p = 0.002, Mann-Whitney U test). The T2-FLAIR mismatch sign correlated with lower
Identifiants
pubmed: 37589920
doi: 10.1007/s11060-023-04417-0
pii: 10.1007/s11060-023-04417-0
doi:
Substances chimiques
Methionine
AE28F7PNPL
Racemethionine
73JWT2K6T3
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
257-265Subventions
Organisme : Japan Society for the Promotion of Science
ID : 20K09321
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Tomczak K, Czerwińska P, Wiznerowicz M (2015) The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn) 19(1A):A68–77. https://doi.org/10.5114/wo.2014.47136
doi: 10.5114/wo.2014.47136
pubmed: 25691825
Louis DN, Perry A, Reifenberger G, Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the Central Nervous System: a summary. Acta Neuropathol 131(6):803–820. https://doi.org/10.1007/s00401-016-1545-1
doi: 10.1007/s00401-016-1545-1
pubmed: 27157931
Komori T (2017) The 2016 WHO classification of Tumours of the Central Nervous System: the major points of revision. Neurol Med Chir (Tokyo) 57(7):301–311. https://doi.org/10.2176/nmc.ra.2017-0010
doi: 10.2176/nmc.ra.2017-0010
pubmed: 28592714
van den Bent MJ, Looijenga LHJ, Langenberg K, Dinjens W, Graveland W, Uytdewilligen L, Smitt PAS, Jenkins RB, Kroset JM (2003) Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 97(5):1276–1284. https://doi.org/10.1002/cncr.11187
doi: 10.1002/cncr.11187
pubmed: 12599236
van den Bent MJ, Brandes AA, Taphoorn MJB, Kros JM, Kouwenhoven MCM, Delattre JY, Bernsen HJJA, Frenay M, Tijssen CC, Grisold W, Sipos L, Enting RH, French PJ, Dinjens WNM, Vecht CJ, Allgeier A, Lacombe D, Gorlia T, Hoang-Xuanet K (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31(3):344–350. https://doi.org/10.1200/JCO.2012.43.2229
doi: 10.1200/JCO.2012.43.2229
pubmed: 23071237
Brat DJ, Verhaak RGW, Aldape KD et al (2015) Comprehensive, integrative genomic analysis of diffuse Lower-Grade Gliomas. N Engl J Med 372(26):2481–2498. https://doi.org/10.1056/NEJMoa1402121 . Epub 2015 Jun 10
doi: 10.1056/NEJMoa1402121
pubmed: 26061751
Suzuki H, Aoki K, Chiba K et al (2015) Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 47(5):458–468. https://doi.org/10.1038/ng.3273 . Epub 2015 Apr 13
doi: 10.1038/ng.3273
pubmed: 25848751
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 World Health Organization classification of tumors of the Central Nervous System: a summary. Neuro Oncol 23(8):1231–1251. https://doi.org/10.1093/neuonc/noab106
doi: 10.1093/neuonc/noab106
pubmed: 34185076
pmcid: 8328013
Wijnenga MMJ, French PJ, Dubbink HJ, Dinjens WNM, Atmodimedjo PN, Kros JM, Smits M, Gahrmann R, Rutten GJ, Verheul JB, Fleischeuer R, Dirven CMF, Vincent AJPE, van den Bent MJ (2018) The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis. Neuro Oncol 20(1):103–112. https://doi.org/10.1093/neuonc/nox176
doi: 10.1093/neuonc/nox176
pubmed: 29016833
Delev D, Heiland DH, Franco P, Reinacher P, Mader I, Staszewski O, Lassmann S, Grau S, Schnell O (2019) Surgical management of lower-grade glioma in the spotlight of the 2016 WHO classification system. J Neurooncol 141(1):223–233. https://doi.org/10.1007/s11060-018-03030-w . Epub 2018 Nov 22
doi: 10.1007/s11060-018-03030-w
pubmed: 30467813
Patel SH, Poisson LM, Brat DJ, Zhou Y, Cooper L, Snuderl M, Thomas C, Franceschi AM, Griffith B, Flanders AE, Golfinos JG, Chi AS, Jain R (2017) T2-FLAIR mismatch, an imaging biomarker for IDH and 1p/19q status in Lower-grade gliomas: a TCGA/TCIA project. Clin Cancer Res 23(20):6078–6085. https://doi.org/10.1158/1078-0432.CCR-17-0560
doi: 10.1158/1078-0432.CCR-17-0560
pubmed: 28751449
Broen MPG, Smits M, Wijnenga MMJ, Dubbink HJ, Anten MHME, Schijns OEMG, Beckervordersandforth J, Postma AA, van den Bent MJ (2018) The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study. Neuro Oncol 20(10):1393–1399. https://doi.org/10.1093/neuonc/noy048
doi: 10.1093/neuonc/noy048
pubmed: 29590424
pmcid: 6120363
Lasocki A, Gaillard F, Gorelik A, Gonzales M (2018) MRI features can predict 1p/19q status in intracranial gliomas. AJNR Am J Neuroradiol 39(4):687–692. https://doi.org/10.3174/ajnr.A5572 . Epub 2018 Mar 8
doi: 10.3174/ajnr.A5572
pubmed: 29519793
pmcid: 7410766
Batchala PP, Muttikkal TJE, Donahue JH, Patrie JT, Schiff D, Fadul CE, Mrachek EK, Lopes MB, Jain R, Patel SH Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in IDH-Mutant Lower Grade Gliomas AJNR Am J Neuroradiol 40(3):426–432. https://doi.org/10.3174/ajnr.A5957 . Epub 2019 Jan 31
Juratli TA, Tummala SS, Riedl A, Daubner D, Hennig S, Penson T, Zolal A, Thiede C, Schackert G, Krex D, Miller JJ, Cahill DP (2019) Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups. J Neurooncol 141(2):327–335. https://doi.org/10.1007/s11060-018-03034-6 . Epub 2018 Dec 7
doi: 10.1007/s11060-018-03034-6
pubmed: 30536195
Deguchi S, Oishi T, Mitsuya K, Kakuda Y, Endo M, Sugino T, Hayashi N (2020) Clinicopathological analysis of T2-FLAIR mismatch sign in lower-grade gliomas. Sci Rep 10(1):10113. https://doi.org/10.1038/s41598-020-67244-7
doi: 10.1038/s41598-020-67244-7
pubmed: 32572107
pmcid: 7308392
Foltyn M, Taborda KNN, Neuberger U, Brugnara G, Reinhardt A, Stichel D, Heiland S, Herold-Mende C, Unterberg A, Debus J, von Deimling A, Wick W, Bendszus M, Kickingereder P (2020) T2/FLAIR-mismatch sign for noninvasive detection of IDH-mutant 1p/19q non-codeleted gliomas: validity and pathophysiology. Neurooncol Adv 2(1):vdaa004. https://doi.org/10.1093/noajnl/vdaa004 . eCollection 2020 Jan-Dec
doi: 10.1093/noajnl/vdaa004
pubmed: 32642675
pmcid: 7212872
Goyal A (2020) Erratum. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a bayesian approach to evaluation of diagnostic test performance. Neurosurg Focus 48(5):E10. https://doi.org/10.3171/2020.3.FOCUS19660a
doi: 10.3171/2020.3.FOCUS19660a
pubmed: 32357319
Jain R, Johnson DR, Patel SH, Castillo M, Smits M, van den Bent MJ, Chi AS, Cahill DP (2020) Real world” use of a highly reliable imaging sign: “T2-FLAIR mismatch” for identification of IDH mutant astrocytomas. Neuro Oncol 22(7):936–943. https://doi.org/10.1093/neuonc/noaa041
doi: 10.1093/neuonc/noaa041
pubmed: 32064507
pmcid: 7339896
Corell A, Vega SF, Hoefling N, Carstam L, Smits A, Bontell TO, Björkman-Burtscher IM, Carén H, Jakola AS (2020) The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas: a population-based study. BMC Cancer 20(1):450. https://doi.org/10.1186/s12885-020-06951-w
doi: 10.1186/s12885-020-06951-w
pubmed: 32434559
pmcid: 7238512
Kinoshita M, Arita H, Takahashi M, Uda T, Fukai J, Ishibashi K, Kijima N, Hirayama R, Sakai M, Arisawa A, Takahashi H, Nakanishi K, Kagawa N, Ichimura K, Kanemura Y, Narita Y, Kishima H (2020) Impact of Inversion Time for FLAIR Acquisition on the T2-FLAIR mismatch detectability for IDH-Mutant, Non-CODEL astrocytomas. Front Oncol 10:596448. https://doi.org/10.3389/fonc.2020.596448 . eCollection 2020
doi: 10.3389/fonc.2020.596448
pubmed: 33520709
Lee MK, Park JE, Jo Y, Park SY, Kim SJ, Kim HS (2020) Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign. Eur Radiol 30(2):844–854. https://doi.org/10.1007/s00330-019-06395-2 . Epub 2019 Aug 24
doi: 10.1007/s00330-019-06395-2
pubmed: 31446467
Nojiri T, Nariai T, Aoyagi M, Senda M, Ishii K, Ishiwata K, Ohno K (2009) Contributions of biological tumor parameters to the incorporation rate of L: -[methyl-(11)C] methionine into astrocytomas and oligodendrogliomas. J Neurooncol 93(2):233–241. https://doi.org/10.1007/s11060-008-9767-2 . Epub 2008 Dec 20
doi: 10.1007/s11060-008-9767-2
pubmed: 19099197
Shinozaki N, Uchino Y, Yoshikawa K, Matsutani T, Hasegawa A, Saeki N, Iwadate Y (2011) Discrimination between low-grade oligodendrogliomas and diffuse astrocytoma with the aid of 11 C-methionine positron emission tomography. J Neurosurg 114(6):1640–1647. Epub 2011 Jan 7
doi: 10.3171/2010.11.JNS10553
pubmed: 21214332
Sadeghi N, Salmon I, Levivier CDM, Metens T, Wikler D, Denolin V, Rorive S, Massager N, Baleriaux D, Goldman S (2007) Stereotactic comparison among cerebral blood volume, methionine uptake, and histopathology in brain glioma. AJNR Am J Neuroradiol 28(3):455–461
pubmed: 17353312
pmcid: 7977817
Nariai T, Tanaka Y, Wakimoto H, Aoyagi M, Tamaki M, Ishiwata K, Senda M, Ishii K, Hirakawa K, Ohno K (2005) Usefulness of L-[methyl-11 C] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J Neurosurg 103(3):498–507. https://doi.org/10.3171/jns.2005.103.3.0498
doi: 10.3171/jns.2005.103.3.0498
pubmed: 16235683
Ogishima T, Tamura K, Kobayashi D, Inaji M, Hayashi S, Tamura R, Nariai T, Ishii K, Maehara T (2017) ATRX status correlates with 11 C-methionine uptake in WHO grade II and III gliomas with IDH1 mutations. Brain Tumor Pathol 34(1):20–27. https://doi.org/10.1007/s10014-017-0280-1 . Epub 2017 Mar 1
doi: 10.1007/s10014-017-0280-1
pubmed: 28251430
Recuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, Koelsche C, Schwizer L, Korshunov A, Jones DTW, Hovestadt V, Mittelbronn M, Schittenhelm J, Herold-Mende C, Unterberg A, Platten M, Weller M, Wick W, Pfister SM, von Deimling A (2015) ATRX and IDH1-R132H immunohistochemistory with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol 129:133–146. https://doi.org/10.1007/s00401-014-1370-3 . Epub 2014 Nov 27
doi: 10.1007/s00401-014-1370-3
Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48(3):452–458. https://doi.org/10.1038/bmt.2012.244 . Epub 2012 Dec 3
doi: 10.1038/bmt.2012.244
pubmed: 23208313
Leu K, Ott GA, Lai A, Nghiemphu PL, Pope WB, Yong WH, Liau LM, Cloughesy TF, Ellingson BM (2017) Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas. J Neurooncol 134(1):177–188. https://doi.org/10.1007/s11060-017-2506-9 . Epub 2017 May 25
doi: 10.1007/s11060-017-2506-9
pubmed: 28547590
pmcid: 7927357
Saito T, Muragaki Y, Maruyama T, Komori T, Tamura M, Nitta M, Tsuzuki S, Kawamata T (2016) Calcification on CT is a simple and valuable preoperative indicator of 1p/19q loss of heterozygosity in supratentorial brain tumors that are suspected grade II and III gliomas. Brain Tumor Pathol 33(3):175–182. https://doi.org/10.1007/s10014-016-0249-5 . Epub 2016 Feb 5
doi: 10.1007/s10014-016-0249-5
pubmed: 26849373
Ninatti G, Sollini M, Bono B, Gozzi N, Fedorov D, Antunovic L, Gelardi F, Navarria P, Politi LS, Pessina F, Chiti A (2022) Preoperative [11 C]methionine PET to personalize treatment decisions in patients with lower-grade gliomas. Neuro Oncol 1(24):1546–1556. https://doi.org/10.1093/neuonc/noac040
doi: 10.1093/neuonc/noac040
Okita Y, Kinoshita M, Goto T, Kagawa N, Kishima H, Shimosegawa E, Hatazawa J, Hashimoto N, Yoshimine T (2010) (11)C-methionine uptake correlates with tumor cell density rather than with microvessel density in glioma: a stereotactic image-histology comparison. NeuroImage 49(4):2977–2982
doi: 10.1016/j.neuroimage.2009.11.024
pubmed: 19931401
Kracht LW, Friese M, Herholz K, Schroeder R, Bauer B, Jacobs A, Heiss WD (2003) Methyl-[11 C]- l-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging 30(6):868–873. https://doi.org/10.1007/s00259-003-1148-7
doi: 10.1007/s00259-003-1148-7
pubmed: 12692687
Fuchs BC, Bode BP (2005) Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol 15(4):254–266. https://doi.org/10.1016/j.semcancer.2005.04.005
doi: 10.1016/j.semcancer.2005.04.005
pubmed: 15916903
Kaschten B, Stevenaert A, Sadzot B, Deprez M, Degueldre C, Fiore GD Reznik ALM preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 39(5):778–785